ML390 is a novel potent inhibitor of human DHODH (Dihydroorotate dehydrogenase) that induces differentiation in acute myeloid leukemia (AML) with EC50 of 1.8μM, 8.8μM, 6.5μM, and 0.56μM in ER-HOX-GFP, U937, THP-1 cells and DHODH enzyme, respectively. ML390 was identified as the most potent compound against the engineered ERHOX-GFP cell line.

PfDHODH-IN-2, a dihydrothiophenone derivative (Compound 11), is a Novel and potent Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor with an IC50 of 1.11 µM.

BAY-2402234 is a novel, potent/low-nanomolar and selective inhibitor of dihydroorotate dehydrogenase (DHODH) that has the potential for the treatment of myeloid malignancies.

AG 636 (AG636; AG-636) is a novel,potent, reversible, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor (IC50=17 nM) which has strong anticancer effects.